Presentation:  Current Challenges and Emerging Therapies in MS
> Pretest


1. In the 2017 updates to McDonald criteria, oligoclonal bands:

a. No longer appear in progressive MS diagnostic criteria

b. Returned to relapsing MS diagnostic criteria to establish dissemination in space

c. Returned to relapsing MS diagnostic criteria to establish dissemination in time

d. Were unchanged from their significance in 2010 McDonald criteria.

2. The modified Rio scoring:

a. Guides clinician on when to start immunotherapy in relapsing multiple sclerosis

b. Guides clinicians on when to stop immunotherapy in progressive MS

c. Guides clinicians on when it is appropriate to transition to a different immunotherapy due to incomplete efficacy.

d. Guides clinicians on when it is appropriate to transition to a different immunotherapy due to intolerable side effects.